Launch of Lenacapavir a game-changer

South Africa officially launched Lenacapavir, a long-acting injectable HIV prevention drug, on Friday, June 5, 2026, at Lilian Ngoyi Stadium in Secunda, Mpumalanga. President Cyril Ramaphosa and Health Minister Dr Aaron Motsoaledi led the event, fulfilling a commitment announced in the February 2026 State of the Nation Address. Lenacapavir, administered twice yearly, aims to overcome barriers faced by daily oral PrEP, offering greater discretion and convenience for users, particularly high-risk groups like adolescent girls, pregnant and breastfeeding mothers, and transgender individuals. The rollout prioritizes 360 health facilities in high-burden districts, with the first batch of 37,920 doses arriving in April 2026. The government plans to distribute the drug to vulnerable populations, including female sex workers, men having sex with men, and injecting drug users. The South African National AIDS Council (SANAC) described the launch as a 'new chapter in HIV prevention,' emphasizing collaboration between government, civil society, and private sector partners. Since 2010, South Africa has expanded HIV treatment access, increasing life expectancy from 54 to 66.9 years by 2025 and reducing maternal mortality from 240 to 89 deaths per 100,000 live births by 2020. Despite 8.15 million people living with HIV (12.9% of the population), the Department of Health reports progress in reducing HIV-related deaths through expanded care. The launch coincides with the 25th anniversary of Nkosi Johnson’s passing, a pivotal HIV/AIDS activist who died at age 12 in 2001. Lenacapavir, classified as a preventive medicine—not a vaccine—works as an HIV-1 capsid inhibitor. The drug’s arrival follows years of progress in South Africa’s HIV response, including the world’s largest counseling, testing, and treatment campaign launched in 2010. Minister Motsoaledi confirmed stocks were delivered ahead of the launch, with plans to scale distribution nationwide in the coming months.